1 Mortality and lost to follow-up among Tuberculosis patients on

- 2 treatment in Meru County, Kenya: a retrospective cohort study.
- 3 Authors

6 7

11

12

13

14

20

21

22

- 4 Moses M. Ngari^{1,2}, Jane K. Mberia², Eunice Kanana³, Deche Sanga⁴, Martin K. Ngari⁵, David N. Nyagah²,
- 5 Osman A. Abdullahi².
 - Affiliations
- 8 ¹KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya, ²Department of Public Health, School of Health &
- 9 Human Sciences, Pwani University, Kilifi, Kenya, ³Meru County TB Control Program, Meru, Kenya, ⁴Kilifi County
- 10 TB Control Program, Kilifi, Kenya, ⁵Makueni County Referral Hospital, Wote, Kenya.

- 15 Corresponding Author:
- 16 Dr Moses M. Ngari
- 17 KEMRI–Wellcome Trust Research Programme,
- 18 P.O Box 230-80108, Kilifi, Kenya.
- 19 Email: mngari@kemri-wellcome.org
- 23 SHORT TITLE: TB treatment outcomes in Meru County, Kenya.

Abstract

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Tuberculosis (TB) remains a leading cause of death globally. Patients who get lost-to-follow-up (LTFU) during TB treatment have high risk of relapse, mortality, treatment failure and developing Multidrug resistant TB. Empirical data to monitor long-term TB treatment outcomes in low-andmiddle income countries (LMICs) are sparse. We determined proportion of TB patients who die or are LTFU during six months of treatment and identified factors independently associated with mortality or LTFU. A retrospective cohort using data from routine Meru County TB surveillance system. We included 38020 records of TB patients aged >15 years on treatment 2012 to 2022. TB treatment outcomes of interest were LTFU or death within six months of treatment. Survival analyses accounting for competing events were performed. Among the 38020 patients included, 27608 (73%) were male and the median (IQR) age was 32 [25-42] years. 26599 (70%) had bacteriologically confirmed TB while 11421 (30%) were clinically diagnosed. During 16531 person-years of follow-up, 2385 (6.3%, 95%CI 6.0–6.5) and 1942 (5.1%, 95%CI 4.9–5.3) patients were LTFU and died respectively. In the multivariable model, patients on re-treatment after LTFU or after failure and those previously treated compared to new TB patients were positively associated with LTFU. Patients coinfected with HIV and those with unknown HIV status were positively associated with LTFU. In contrast, females, clinically diagnosed, extra-pulmonary TB and older patients were negatively associated with LTFU. Patients HIV infected on ARVs, not on ARVs and unknown HIV status versus not infected were positively associated with mortality. Other comorbidities (not HIV), clinically diagnosed, undernourished and older patients were positively associated with mortality. More than 10% of TB patients either die or are LTFU before completing treatment. TB patients on re-treatment, HIV infected, clinically diagnosed,

- 47 undernourished and the elderly needs more targeted interventions to improve survival and
- successfully treatment.

- **Key words:** Tuberculosis; Mortality; Lost-to-follow-up; Treatment outcomes; low-and-middle
- 51 income countries; Africa.

Introduction

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Tuberculosis (TB) is a curable disease; however, it remains one of the leading causes of death globally [1-4]. In 2022, it was the second leading cause of death globally from a single infectious agent after COVID-19[4]. Up to 11.4million people developed TB in 2022 in the whole world[4]. The United Nations Sustainable Development Goals (SDG-3) set an ambitious target to end the TB epidemic in 2030 by reducing the TB incidence by 80% and TB deaths by 90% from the 2015 levels. Despite the progress made in TB diagnosis through use of rapid culture/molecular techniques such as Xpert MTB/RIF assay, and clinical management, the global targets (SDG-3) are off-track [5]. In 2022, TB is estimated to have caused 1.3 million deaths, a reduction of 19% since 2015, which is below the End TB Strategy target of reducing TB deaths by 75% before 2025 [4, 5]. Sub-Saharan Africa and South-East Asia continue to bare the highest burden of TB deaths, accounting for 81% of deaths in 2022[4, 6]. HIV which is endemic in Sub-Saharan Africa is one of the leading causes of deaths among people living with HIV (PLWHIV) and co-infected with TB despite the high uptake of ARVs [7-10]. Kenya is among the 30 high TB burden countries that contributed 87% of the global cases in 2022 [4]. Lost to follow-up (LTFU) during TB treatment remains another major threat to successful TB treatment. Patients who interrupt TB treatment have high risk of relapse, mortality, treatment failure and developing Multidrug resistant TB[11]. This means they remain infectious for longer period and therefore continue transmitting TB in the community[11]. Most studies usually report poor TB treatment outcome (combined treatment failure, death, lost to follow-up and not evaluated) and not LTFU separately. In China as high as 13% adult TB patients were LTFU from 2017 to 2021, while retreated patients and those with underlying medical conditions like hepatitis

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

and cirrhosis were more likely to default treatment[12]. In Ethiopia, among children and adult patients, 5.36% and 16.6% were LTFU respectively while 13% were LTFU in urban informal settlement in Kenya[13-15]. Among multidrug resistant TB patients, up to 17% are LTFU before completing treatment[16]. However, in Brazil and Mozambique 18.1% and a high of 44.9% were LTFU respectively[17, 18]. It is highly likely both mortality and LTFU during TB treatment will vary depending on the incidence of TB, prevalence of underlying medical conditions like HIV, incidence of multidrug resistant TB and access to health care. In Kenya, a few studies have studied mortality and LTFU during TB treatment[15, 19-21], with some studies focusing on select population like paediatrics only[22]. Currently, there is limited empirical data to monitor long-term TB treatment outcomes in low-and-middle income countries (LMICs) and how the outcomes are impacted by evolving epidemiology of both infectious and noncommunicable diseases such as HIV, COVID-19, diabetes, hypertension and malnutrition. We aimed to determine proportion of TB patients who die or are LTFU during six months of TB treatment in Meru County, Kenya and identify factors independently associated with mortality (adjusted for competing risk of LTFU) or LTFU (adjusted for competing risk of mortality).

Materials and Methods

Study design

93

94

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

- 95 A retrospective cohort using data from routine standard National Leprosy and Tuberculosis and
- 96 Lung Disease (NTLD) register.

Study settings

The study analysed routine data from the TB electronic surveillance system from Meru County in Kenya. Meru County is located east of Mt Kenya with an estimated population of 1.5 million people in the 2019 census. Its population density in 2019 was 220 people per Sq.Km. The major economic activities are agriculture with Tea, Coffee, Khat, Bananas and Avocado as the top cash crops. The county is served by one regional referral hospital and approximately 176 public health facilities. The HIV prevalence in Meru County was 2.6% in 2020 and the ART coverage was 70%[23] The county follows the Kenya national guidelines to diagnose and treat presumptive TB cases[24]. TB patients are diagnosed using World Health Organization (WHO)-recommended molecular TB diagnostics (Xpert MTB/RIF), smear microscopy and culture. Additionally, extrapulmonary cases and those diagnosed based on clinical symptoms, suggestive histological examination or X-ray abnormalities without laboratory confirmation are clinically diagnosed and started on TB treatment. New TB patients are considered drug-susceptible and take Rifampicin (R), Isoniazid (H), Pyrazinamide (Z) and Ethambutol (E) during the intensive phase (first two months) followed by four months of treatment on Rifampicin (R) and Isoniazid (H) (2RHZE/4RH). However, new patients diagnosed with TB but with other complications such as meningitis and osteo-articular TB are treated with RHZE for the first two months followed by Rifampicin (R) and Isoniazid (H) for ten months (2RHZE/10RH). TB patients who previously had been on anti-TB including relapsed cases, were retreated in the first two months with Streptomycin (S), Ethambutol (E), Rifampicin (R), Isoniazid (H) and Pyrazinamide (Z), followed by Ethambutol (E), Rifampicin (R), Isoniazid (H) and Pyrazinamide (Z) for one month and Ethambutol (E), Rifampicin (R) and Isoniazid (H) for five months (2SRHZE/1RHZE/5RHE). The 2SRHZE/1RHZE/5RHE regimen was phased out in 2020 and replaced with 2RHZE/4RH. All TB patients are systematically screened for malnutrition and offered HIV test at the time of starting TB treatment. Undernourished patients are offered nutritional support while HIV infected are referred to Comprehensive Care Center (CCC) which offers HIV management care. In all Kenya government health facilities, TB and HIV diagnosis and treatment are offered for free.

Study Population

- We included records of TB patients starting treatment within Meru County aged 15 years and
- above from January 2012 to December 2022 and registered in the County TB surveillance system.

127 Data source and variables.

Data used in this study were extracted from the Treatment Information from Basic Unit (TIBU) Meru County TB Electronic surveillance on 20th May 2024. Kenya transitioned from paper-based reporting to a national electronic surveillance system i.e TIBU in 2012. The system is operational in all Counties in Kenya that captures and stores individual-level TB patient data which is reported to the Kenya national TB program. At each health facility, data are recorded into TB registers which are periodically transcribed electronically using tablets and synchronized to the national server[25]. Patients diagnosed with TB while in the wards are linked with outpatient TB clinics where they get registered in the TIBU system. The study included the following variables collected in the routine data; demographic (age, sex), sub-counties, date of starting TB treatment, Clinical features including type of TB (pulmonary or extra-pulmonary), new or retreated patients, HIV status, other underlying medical conditions, TB diagnosis (either bacteriological or clinical),

treatment regimen, Body Mass Index (BMI) a proxy for nutritional status, nutritional support provided and the type of direct observed treatment provided. A new patient was a presumptive TB case who has never been on TB treatment or had taken anti-TB medication for less than one month. TB patients on retreatment included; a) relapsed patients who were declared as completed treatment or cured but has been diagnosed with recurrent episode, b) treatment failures who included previously treated patients whose treatment outcome was declared as failure, c) treatment after loss-to-follow-up included patients previously treated but were categorized as lost-to-follow-up and d) other previously treated included those previously treated but outcome was unknown. The outcomes of interest were the WHO TB treatment outcomes either death or lost-to-follow-up during six months of treatment. The deaths included TB patients who died for any reason on or after starting treatment but within the six months of follow-up. Lost-to-follow-up was defined to include TB patient who started TB treatment but was interrupted for at least two consecutive months[26]. Treatment success was used to define those who completed at least six months of TB treatment without evidence of treatment failure and those cured.

Study size

Data from 38020 presumptive TB patients on treatment from 2012 to 2022 within Meru County were included in the study. The study size (N=38020) had a power of at least 90% to detect a hazard ratio \geq 2.0 of HIV infected compared to HIV negative or clinical versus bacteriologically diagnosed TB being associated with mortality assuming 5% overall probability of death and two-tailed alpha of 0.05[10, 27].

Statistical analysis

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

Data shared by the County TB coordinator were checked for completeness and processed for analysis. We found all records had a treatment outcome since we got data after at least one year of starting treatment (i.e. the last patient in the data started treatment on 31st December 2022 meaning they had completed treatment by 20th May 2024 when data were extracted). We assessed the pattern of missing data in the other variables and found low proportion (<10%) of missing data in HIV and BMI variables. The missing records were associated with the outcomes of interest and therefore were assumed not to be missing at random. Among the HIV and BMI variables, an extra category called 'unknown' was added to represent the missing data and included in the analysis. The continuous BMI was categorized into: undernourished (BMI<18.5), normal (BMI 18.5 to 25) and overweight (BMI≥25). Age in years was categorized into groups of ten years apart from the open ended \geq 65 years. The data are reported as frequencies and proportions. Mortality and LTFU are reported as proportions with binomial exact 95% confidence interval. A non-parametric Wilcoxon-type test for trend was used to evaluate evidence of linear trend in annual proportion of deaths and LTFU from 2012 to 2022 [28]. Survival analysis was used to examine time to either death or LTFU after starting TB treatment and independent factors associated with the two outcomes separately. Person time was calculated from date of starting TB treatment up to date of the event or six months later (for those who completed treatment). Mortality and LTFU rates are reported as number of events per 1000 person-years and compared across groups using log-rank test. We tested proportionalhazards (PH) assumption using scaled Schoenfeld residuals and found no evidence of PH violation for both outcomes. Time to event were plotted using Nelson-Aalen Cumulative hazard curves. To assess the effects of independent exposures on time to death or LTFU, two separate multilevel survival regression models were fixed for each outcome accounting for heterogeneity by subCounties. For the death outcome, we treated LTFU and transfer outside Meru County during the course of the six months as competing event because they precluded the probability of observing the event of interest (death). While for the LTFU outcome, deaths and transfer outside Meru County were treated as competing events. Therefore, the Fine and Gray competing risk method was used to examine independent factors associated with death or LTFU accounting for the sub-Counties heterogeneity and reported sub-distribution hazards ratios (SHR) as the measure of effects and their respective 95% confidence intervals[29]. We performed univariate analysis including only one independent variable and reported the crude SHR. To build multivariable models, we retained independent variables with P-value<0.1 using backwards stepwise approach and reported adjusted SHR in the final model. All statistical analyses were conducted using STATA version 17.0 (StataCorp, College Station, TX, USA) and R (version 4.2.0).

Ethical consideration

Ethical approval was granted by the Pwani University Ethics Review Committee (ISERC/PU-STAFF/003/2024) and permit to conduct the study granted by Department of Health, Meru County (MRU/GEN/GEN/C.50). Study participants and caregivers for children less than eighteen years old provided written informed consent for their data to be used. The analyses used anonymized data. The study is reported following STrengthening the Reporting of OBservation studies in Epidemiology (STROBE) [30] and REporting of studies COnducted using Observational Routinely-collected health Data (RECORD) [31].

Results

Patient Characteristics

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

During the review period, 42116 TB patients were started on treatment of which 38020/42116 (90%) were ≥15 years old and included in this study. They included 27,608 (73%) male and their median (interquartile range - IQR) age was 32 [25–42] years. The patients were relatively young with over 50% younger than 35 years. The patients were more frequently from a public health facility. Approximately one third (n=12573, 33%) had normal BMI and only 4.0% were overweight. Bacteriologically confirmed TB cases were 26599 (70%) while 11421 (30%) were diagnosed based on clinical signs and abnormal Xray suggestive of TB. Among the 26599 bacteriologically confirmed cases, 10480 (39%) had both sputum smear positive and GenXpert result, 14419 (54%) were sputum smear positive only while 1700 (6.4%) were GenXpert positive only. A total of 33979 (89%) patients were new TB cases, 2333 (6.1%) were on retreatment after relapse, 596 (1.6%) were being retreated after LTFU (they were actively traced and restarted on treatment) and 652 (1.7%) were transferred into Meru County having started treatment in other Counties. There were 6773 (18%) TB patients co-infected with HIV while 1061 (2.8%) had unknow HIV status. Among the 6773 HIV infected patients, 6350 (94%) and 6698 (99%) were on ARVs and cotrimoxazole prophylaxis respectively. Overall, 280 (0.7%) had other comorbidities other than HIV. The most frequent comorbidities were:125 diabetes cases, 92 cases of hypertension and 29 cases of mental health conditions (S1 Fig). One thousand five hundred and ninety-four (4.2%) were on recreation drugs. The most frequent direct observed treatment was family-based (n=35415, 93%). Thirty-six thousands and eleven (95%) were on the six-months first line treatment regimen of 2-month intensive phase of Rifampin (R), Isoniazid (H), Pyrazinamide (Z) and Ethambutol (E) followed by 4-month phase of Rifampin (R) and Isoniazid (H) (2RHZE/4RH) Table 1.

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

Clinical diagnosis, extrapulmonary TB and other comorbidities apart from HIV were more frequent among the elderly (all P-values<0.001) (S1 Table). HIV infection was more frequent among females, clinically diagnosed and extra-Pulmonary TB cases (all P-values<0.001) (S2 Table). **Treatment outcome** A total of 32194/38020 (85%) successfully completed at least six months of TB treatment, of which 13988/32194 (43%) were cured. There was no evidence of linear trend in annual proportion of patients who completed treatment from 2012 to 2022 (Trend P-value=0.70) Fig 1a. Two thousand three hundred and eighty-five (6.3%), 1942 (5.1), 830 (2.2%), 342 (0.9%) and 327 (0.9%) were LTFU, died, transferred out of their treatment facility, failed treatment and developed resistant and were moved to the drug-resistant cohort respectively (S2 Fig). Follow-up time and rates The patients were on follow-up for 16531 person-years. During treatment, 2385 (6.3%, 95%CI 6.0 to 6.5) patients were lost to follow-up; incidence rate was 144 (95%CI 139–150) LTFU/1000 person-years. The median [IQR] time to LTFU was 68 [35–112] days. A total of 1084/2385 (45%) LTFU occurred within the first two months of intensive treatment, while cumulatively 1529/2385 (64%) LTFU occurred within three months of starting TB treatment. There was no evidence of linear trend in the annual LTFU rates from 2012 to 2022 (Trend P-value=0.06) Fig 1b. One thousand nine hundred and forty-two (5.1%, 95%CI 4.9 to 5.3) patients died: incidence rate of 117 (95%CI 112 to 123) deaths/1000 person-years. The median [IQR] time to death was 43 [18–88] days. A total of 1178/1942 (61%) deaths occurred within the first two months of intensive treatment, while cumulatively 1483/1942 (76%) deaths occurred within three months of starting

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

TB treatment. There was no evidence of linear trend in the annual mortality rates from 2012 to 22 (Trend P-value=0.11) **Fig 1b**. LTFU and mortality rates per 1000 person-years are shown in Table 2. The rate of LTFU was highest in Igembe North Sub- County (196, 95%CI 177 to 218)/1000 person-years) and lowest in Meru Central Sub- County (53, 95%CI 42 to 67)/1000 person-years), Log-rank P-value<0.001 (Fig 2c). Mortality rate was highest in Imenti North Sub- County (142, 95%CI 129 to 158)/1000 person-years) and lowest in Igembe North Sub-County (91, 95%CI 78 to 106)/1000 person-years), Log-rank P-value<0.001 (Fig 2d). The rates of LTFU were not significantly different between patients with and without other comorbidity (Not HIV), on versus not on recreation drugs and across the DOT approaches (all log-rank test P-values >0.05). Mortality rates were not significantly different between patients on versus not on recreation drugs and across the DOT approaches (all log-rank test P-values >0.05) **Table 2**. Factors associated with LTFU or mortality. All the exposure variables explored for association with LTFU in the univariable analysis are shown in S3 Table. In the multivariable analysis, patients on re-treatment after LTFU (aSHR 3.28 (95%CI 2.59–4.17)) or after failure (aSHR 1.65 (95%CI 1.27–2.14)) and those previously treated (aSHR 2.11 (95%CI 1.66–2.68)) had higher hazard of LTFU compared to new TB cases (Fig 2a). Patients coinfected with HIV (on and not on ARVs) and those with unknown HIV status were positively associated with LTFU (Fig 2b). Compared to the first-line treatment regimen, those on longer treatment period i.e 2SRHZE/1RHZE/5RHE had 34% higher hazard of being LTFU (aSHR 1.34 (95%CI 1.13–1.58)). In contrast, female patients were 36% less likely to be LTFU (aSHR 0.64 (95%CI 0.60–0.69)) and older patients had significantly lower hazard of LTFU relative to younger ones. Compared to patients from public health facilities, those from prisons had 38%

lower hazard of LTFU (aSHR 0.62 (95%CI 0.47–0.82)). Clinically diagnosed patients and those with extra-pulmonary TB had lower hazard of LTFU. However, the BMI, other comorbidity (not HIV), on recreation drugs and type of DOT approach were not significantly associated with LTFU (**Table 3**). Age had a linear trend association with mortality where the hazard of death increased from aSHR of 1.57 (25 to 34 years versus <25 years) to aSHR of 5.86 (≥65 years versus <25 years) test for trend P-value <0.001 (Fig 2c). Compared to non-HIV infected, those infected on ARVs (aSHR 2.41 (95%CI 2.04-2.85)), infected and not on ARVs (aSHR 5.03 (95%CI 3.56-7.10)) and unknown HIV status were positively associated with mortality (Fig 2d). Other comorbidities (not HIV) were positively associated with mortality (aSHR 2.67 (95%CI 1.78–4.01)). Compared to bacteriologically diagnosed, clinically diagnosed patients had more than 2fold hazard of death (aSHR 2.22 (95%CI 1.97–2.49)). Undernourished patients had 50% higher hazard of deaths while the years 2021 and 2022 had significant higher mortality relative to 2012. However, patients from prisons had 30% lower hazard of death (aSHR 0.70 (95%CI 0.55–0.90)) compared to those from public health facilities. Patient sex, type of TB, use of recreation drugs and type of DOT were not associated with mortality (Table 3).

Discussion

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

In this large cohort of drug-susceptible TB patients on treatment, we found 5.1% died with no evidence of declining trend over the decade. Despite the improved understanding of the disease epidemiology and the investments in simplified diagnosis and free treatment in all health facilities in Kenya, there was an increase in TB Case Fatality Ratio during the last two years (2021 and 2022) relative to 2012 baseline which could partly be attributable to the disruptive effect of

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

COVID-19 pandemic on health systems. The proportion of patients who died is within the range reported in India, South Africa and previously in Kenya[19, 32, 33]. The first two months during the intensive treatment phase mark the most vulnerable period when almost two-thirds of deaths occurred. The high risk of early deaths could be a sign of poor health system preparedness which delays TB diagnosis and is unresponsive to needs of severely ill patients. In high HIV burden countries, patients co-effected with TB and HIV usually die very early following TB treatment[10, 34, 35]. However, as observed in this study, starting ARV treatment during the intensive treatment phase reduces mortality relative to being HIV infected but not on ARVs[36-38]. In fact, providing ARVs to patients with TB and HIV regardless of starting in the intensive treatment phase, reduces mortality by 44 to 71%[8]. Before 2016, in Kenya, HIV patients started ARVs when they have advanced HIV. However, following the WHO guidelines recommending immediate starting of ARVs upon HIV diagnosis in 2015, Kenya adopted the guidelines in mid-2016[39]. Our results emphasize the need for implementing this policy to improve survival. But it is worth noting that ~3% of the patients had unknown HIV status despite the requirement of systematic screening for HIV among all TB cases for free in Kenya, and that those with unknown HIV status had high risk of mortality. Our results show patients who were elderly, undernourished, HIV infected including those with unknown HIV status, diagnosed using clinical signs, had other comorbidities and being treated after relapse had significantly high risk of death. These were not isolated findings because all these factors have been previously identified as risk factors for death among TB patients[2, 40, 41]. Advancing older age had a linear trend with increasing risk of mortality likely because of weaking immune responses among the elderly and age-related comorbidities which suggest the need for more support and care during TB treatment in this population[2]. As observed in this study and

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

previously, the elderly more frequently had extrapulmonary TB and clinical diagnosis which sometimes are hard to diagnose causing delays in starting TB treatment and thus increased mortality[40, 42]. TB patients who are started on treatment based on clinical diagnosis usually will have a negative smear result and takes time to either diagnose extrapulmonary or start treatment based on the clinical signs which can cause delay in treatment with a possibility of increasing mortality. Clinical diagnosis also has potential to under-diagnose other severe respiratory diseases and is more frequent among patients with HIV infection and the elderly [27, 42]. The finding of patients on treatment after relapse had high risk of death suggests they were not cured which is not surprising given more than one-third of the patients were classified as 'completed treatment' without evidence of negative smear negative test in the last two months of treatment. This could arise because of poor drug adherence, poor drug quality or treatment regimen inadequate for the population. Relapsed patients also include new infection likely caused by community high prevalence of infectious TB or exposure to different *M.tuberculosis* strain[43]. The association with undernutrition was not surprising given it is the leading attributable risk factor for TB and malnourished patients have double risk of death from TB compared to non-malnourished patients[44, 45]. Malnutrition impairs immune response and may alter how drugs are absorbed[44, 46]. We observed a LTFU of ~6% within the six months of TB treatment which did not decline over the decade. It was within the range observed in Ghana (8.6%)[47], 5.3% in Kilifi, Kenya[21] and 6.8% in China[48]. However, it was lower than 13% in urban region in Nairobi, Kenya[15], 18.1% in Brazil[17] and 44.9% in Mozambique[18]. The differences could be due to varying HIV status, study settings and health system support availed to the patients during follow-up. During the intensive phase of TB treatment 45% of all LTFU occurred which was within the pooled range of

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

0% to 85% previously observed [49], highlighting the high risk of LTFU immediately after starting treatment. These patients who are LTFU present a threat because they contribute to TB transmission in the community and acquisition of drug resistance[11]. Unlike the factors positively associated with mortality, elderly patients and those diagnosed using clinical signs had lower risk of LTFU. It is likely these group of patients which had very high risk of death felt adhering to TB treatment and the regular contacts with health workers would be of much benefit to their recovery. However, in Ethiopia, the risk of LTFU was higher among the elderly which could be attributed to varying social support systems available to the elderly in Kenya and Ethiopia[14]. TB patients who are on retreatment after previous treatment either after LTFU or treatment failure had remarkably high risk of LTFU. This highlights a sub-population of TB patients that would benefit from more social support such as the community-based DOT and involvement of family members during the treatment phase. As previously observed, HIV coinfected patients regardless of whether on ARTs or not had higher risk of LTFU which could be attributable to the huge burden of concurrent HIV and TB medication[21]. The introduction of immediate starting of ARVs upon HIV diagnosis has been associated with increased risk of LTFU in Uganda and Ethiopia, calling for a more cautious approach in implementing the policy[50, 51]. It is likely the new HIV diagnosed patients who also have TB are not adequately prepared for the lifelong ART medication in addition to the six months or more TB treatment or may not have severe HIV clinical signs thus likely to default treatment. Females were less likely to be LTFU because males who are predominantly household providers are more economically engaged and thus miss their follow-ups when working[52]. Our findings suggest deaths during TB treatment are predictable and preventable. Deaths mostly occur during the intensive phase of treatment and among the elderly with underlying

comorbidities, advanced HIV infections and low BMI. A comprehensive assessment of the clinical needs for these patients during follow-up should be considered and risk stratified care offered. Future research to develop appropriate clinical support for example criteria for inpatient care referral and monitoring adherence to current guidelines such as systematic screening for HIV and malnutrition, immediate initiation of ARVs to those HIV infected and nutritional support should be prioritized[39, 53]. We also identified LTFU as a significant challenge during TB treatment. A people-centred care recommended by the WHO in the End TB strategy has not been fully adopted in LMICs because of resources constrains[26, 54, 55]. Evidence of type of psychosocial support that works, and how they can be effectively implemented to reduce LTFU in LMICs are inconclusive[55, 56]. A multi-sectoral approach is thus necessary to improve TB successful treatment.

Study strengths and Limitations

The strength of the study was the large number of patients systematically followed up during TB treatment and the availability of detailed TB treatment outcomes (the outcomes and actual dates of the outcomes). This was a passive surveillance using routinely collected data with its inherent limitations. Therefore, the analyses were limited to only available data. Data on adherence to treatment and social economical exposures were not collected. Data to identify patients referred for care from wards and those who got admitted to hospital during the six months of treatment were not available too. The study was only conducted in one County in Kenya and should be interpreted with caution.

Conclusion

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

More than one tenth of TB patients either die or are LTFU before completing treatment. Our findings highlight the high burden of mortality and LTFU during the intensive phase of treatment. Interventions targeting TB patients on re-treatment, HIV infected, clinically diagnosed, undernourished and the elderly provides an opportunity to improve survival and successfully TB treatment. Acknowledgement We acknowledge study participants and Meru County TB program staff who managed and collected data from the patients. We thank Lilian Mwango for help with depositing data and analysis code to the data repository. **Data availability Statement** The study anonymized data and the analyses codes underlying the results presented are archived in the Harvard Dataverse repository: https://doi.org/10.7910/DVN/78JGUE **Author contributions** Conceptualization: Moses M. Ngari, Osman A. Abdullahi Data curation: Eunice Kanana, Jane K. Mberia Formal analysis: Moses M. Ngari Investigation: Eunice Kanana, Jane K. Mberia

Methodology: Moses M. Ngari, Deche Sanga, Martin K. Ngari, David N. Nyagah, Osman A. Abdullahi.

Project administration: Moses M. Ngari, David N. Nyagah, Martin K. Ngari, Eunice Kanana Supervision: Osman A. Abdullahi

Validation: Osman A. Abdullahi

Visualization: Moses M. Ngari

Writing-original draft: Moses M. Ngari

Writing-review & editing: Moses M. Ngari, Jane K. Mberia, Eunice Kanana, Deche Sanga, Martin K. Ngari, David N. Nyagah, Osman A. Abdullahi.

References

- 421 1. Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause
- 422 mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis.
- 423 2019;19(10):1129-37. Epub 2019/07/22. doi: 10.1016/S1473-3099(19)30309-3. PubMed PMID:
- 424 31324519.

- 425 2. Nicholson TJ, Hoddinott G, Seddon JA, Claassens MM, van der Zalm MM, Lopez E, et al. A
- 426 systematic review of risk factors for mortality among tuberculosis patients in South Africa. Syst Rev.
- 2023;12(1):23. Epub 2023/02/24. doi: 10.1186/s13643-023-02175-8. PubMed PMID: 36814335; PubMed Central PMCID: PMCPMC9946877.
- 429 3. Lumu I, Musaazi J, Semeere A, Handel I, Castelnuovo B. Survival and predictors of mortality after
- 430 completion of TB treatment among people living with HIV: a 5-year analytical cohort. BMC Infect Dis.
- 431 2023;23(1):238. Epub 2023/04/19. doi: 10.1186/s12879-023-08217-9. PubMed PMID: 37072726;
- 432 PubMed Central PMCID: PMCPMC10111785.
- 433 4. World Health Organization. Global tuberculosis report 2023. Geneva: : WHO, 2023.
- 434 5. Fukunaga R, Glaziou P, Harris JB, Date A, Floyd K, Kasaeva T. Epidemiology of Tuberculosis and
- 435 Progress Toward Meeting Global Targets Worldwide, 2019. MMWR Morb Mortal Wkly Rep.
- 436 2021;70(12):427-30. Epub 2021/03/26. doi: 10.15585/mmwr.mm7012a4. PubMed PMID: 33764960;
- PubMed Central PMCID: PMCPMC7993552 Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- 439 6. Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis
- 440 mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5(9):e898-e906. Epub
- 2017/08/16. doi: 10.1016/S2214-109X(17)30289-9. PubMed PMID: 28807188; PubMed Central PMCID:
- 442 PMCPMC5556253
- 7. Nliwasa M, MacPherson P, Gupta-Wright A, Mwapasa M, Horton K, Odland JO, et al. High HIV
- and active tuberculosis prevalence and increased mortality risk in adults with symptoms of TB: a
- 445 systematic review and meta-analyses. J Int AIDS Soc. 2018;21(7):e25162. Epub 2018/08/01. doi:
- 446 10.1002/jia2.25162. PubMed PMID: 30063287; PubMed Central PMCID: PMCPMC6067081.
- 447 8. Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RM. The impact of antiretroviral
- therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and
- 449 meta-analysis. PLoS One. 2014;9(11):e112017. Epub 2014/11/13. doi: 10.1371/journal.pone.0112017.
- 450 PubMed PMID: 25391135; PubMed Central PMCID: PMCPMC4229142.
- 451 9. Sullivan A, Nathavitharana RR. Addressing TB-related mortality in adults living with HIV: a review
- of the challenges and potential solutions. Ther Adv Infect Dis. 2022;9:20499361221084163. Epub
- 453 2022/03/25. doi: 10.1177/20499361221084163. PubMed PMID: 35321342; PubMed Central PMCID:
- 454 PMCPMC8935406.
- 455 10. Ngari MM, Rashid MA, Sanga D, Mathenge H, Agoro O, Mberia JK, et al. Burden of HIV and
- 456 treatment outcomes among TB patients in rural Kenya: a 9-year longitudinal study. BMC Infect Dis.
- 457 2023;23(1):362. Epub 2023/05/31. doi: 10.1186/s12879-023-08347-0. PubMed PMID: 37254064;
- 458 PubMed Central PMCID: PMCPMC10227789.
- 459 11. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst
- 460 Rev. 2006;(2):CD003343. Epub 2006/04/21. doi: 10.1002/14651858.CD003343.pub2. PubMed PMID:
- 461 16625579.
- 462 12. Jiang Y, Chen J, Ying M, Liu L, Li M, Lu S, et al. Factors associated with loss to follow-up before
- and after treatment initiation among patients with tuberculosis: A 5-year observation in China. Front
- 464 Med (Lausanne). 2023;10:1136094. Epub 2023/05/14. doi: 10.3389/fmed.2023.1136094. PubMed
- 465 PMID: 37181365; PubMed Central PMCID: PMCPMC10167013.

- 466 13. Belay GM, Wubneh CA. Childhood tuberculosis treatment outcome and its association with HIV
- 467 co-infection in Ethiopia: a systematic review and meta-analysis. Trop Med Health. 2020;48:7. Epub
- 468 2020/02/27. doi: 10.1186/s41182-020-00195-x. PubMed PMID: 32099521; PubMed Central PMCID:
- 469 PMCPMC7027074.
- 470 14. Birhane M, Mekonnen S, Dingeta T, Teklemariam Z. Loss to follow-up tuberculosis treatment
- 471 and associated factors among adults attending at public health facilities in Warder District, Somali
- 472 Regional State, Eastern Ethiopia. Front Public Health. 2023;11:1151077. Epub 2023/05/26. doi:
- 473 10.3389/fpubh.2023.1151077. PubMed PMID: 37234759; PubMed Central PMCID: PMCPMC10208408.
- 474 15. Kizito KW, Dunkley S, Kingori M, Reid T. Lost to follow up from tuberculosis treatment in an
- 475 urban informal settlement (Kibera), Nairobi, Kenya: what are the rates and determinants? Trans R Soc
- 476 Trop Med Hyg. 2011;105(1):52-7. Epub 2010/10/05. doi: 10.1016/j.trstmh.2010.08.015. PubMed PMID:
- 477 20889176.
- 478 16. Walker IF, Shi O, Hicks JP, Elsey H, Wei X, Menzies D, et al. Analysis of loss to follow-up in 4099
- 479 multidrug-resistant pulmonary tuberculosis patients. Eur Respir J. 2019;54(1). Epub 2019/05/11. doi:
- 480 10.1183/13993003.00353-2018. PubMed PMID: 31073080.
- 481 17. Lima S, de Araujo K, Nunes MAP, Nunes C. Early identification of individuals at risk for loss to
- 482 follow-up of tuberculosis treatment: A generalised hierarchical analysis. Heliyon. 2021;7(4):e06788.
- 483 Epub 2021/05/14. doi: 10.1016/j.heliyon.2021.e06788. PubMed PMID: 33981876; PubMed Central
- 484 PMCID: PMCPMC8085707.
- 485 18. Wikman-Jorgensen PE, Morales-Cartagena A, Llenas-Garcia J, Perez-Porcuna TM, Hobbins M,
- Ehmer J, et al. Implementation challenges of a TB programme in rural northern mozambique: evaluation
- 487 of 2012-2013 outcomes. Pathog Glob Health. 2015;109(5):221-7. Epub 2015/08/05. doi:
- 488 10.1179/2047773215Y.0000000027. PubMed PMID: 26239760; PubMed Central PMCID:
- 489 PMCPMC4727574.
- 490 19. Abdullahi OA, Ngari MM, Sanga D, Katana G, Willetts A. Mortality during treatment for
- tuberculosis; a review of surveillance data in a rural county in Kenya. PLoS One. 2019;14(7):e0219191.
- 492 Epub 2019/07/12. doi: 10.1371/journal.pone.0219191. PubMed PMID: 31295277; PubMed Central
- 493 PMCID: PMCPMC6622488.
- 494 20. Wekunda PW, Aduda DSO, Guyah B, Odongo J. Predictors of mortality and survival probability
- 495 distribution among patients on tuberculosis treatment in Vihiga County, Kenya. Afr Health Sci.
- 496 2023;23(1):218-30. Epub 2023/08/07. doi: 10.4314/ahs.v23i1.24. PubMed PMID: 37545936; PubMed
- 497 Central PMCID: PMCPMC10398452.
- 498 21. Katana GG, Ngari M, Maina T, Sanga D, Abdullahi OA. Tuberculosis poor treatment outcomes
- and its determinants in Kilifi County, Kenya: a retrospective cohort study from 2012 to 2019. Arch Public
- 500 Health. 2022;80(1):48. Epub 2022/02/07. doi: 10.1186/s13690-022-00807-4. PubMed PMID: 35123570;
- 501 PubMed Central PMCID: PMCPMC8818215.
- 502 22. Onyango DO, Yuen CM, Masini E, Borgdorff MW. Epidemiology of Pediatric Tuberculosis in
- 503 Kenya and Risk Factors for Mortality during Treatment: A National Retrospective Cohort Study. J Pediatr.
- 504 2018;201:115-21. Epub 2018/06/11. doi: 10.1016/j.jpeds.2018.05.017. PubMed PMID: 29885751.
- 505 23. National AIDS Control Council (NACC). Ministry of Health Kenya. Kenya HIV estimates, Report
- 506 2020. Nairobi: 2020.
- 507 24. Ministry of Health. Guidelines for Management of Tuberculosis and Leprosy in Kenya. Nairobi:
- 508 2013.
- 509 25. Sharma A, Ndisha M, Ngari F, Kipruto H, Cain KP, Sitienei J, et al. A review of data quality of an
- 510 electronic tuberculosis surveillance system for case-based reporting in Kenya. Eur J Public Health.
- 511 2015;25(6):1095-7. Epub 2015/05/27. doi: 10.1093/eurpub/ckv092. PubMed PMID: 26009610; PubMed
- 512 Central PMCID: PMCPMC5017003.

- 513 26. World Health Organization. The end TB strategy. Geneva: World Health Organization. Geneva:
- 514 2015.
- 515 27. Abdullahi O, Moses N, Sanga D, Annie W. The effect of empirical and laboratory-confirmed
- tuberculosis on treatment outcomes. Sci Rep. 2021;11(1):14854. Epub 2021/07/23. doi:
- 517 10.1038/s41598-021-94153-0. PubMed PMID: 34290301; PubMed Central PMCID: PMCPMC8295390.
- 518 28. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4(1):87-90. Epub 1985/01/01. doi:
- 519 10.1002/sim.4780040112. PubMed PMID: 3992076.
- 520 29. Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics.
- 521 2001;2(1):85-97. doi: 10.1093/biostatistics/2.1.85. PubMed PMID: 12933558.
- 522 30. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The
- 523 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines
- for reporting observational studies. Epidemiology. 2007;18(6):800-4. Epub 2007/12/01. doi:
- 525 10.1097/EDE.0b013e3181577654. PubMed PMID: 18049194.
- 526 31. Benchimol El, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of
- 527 studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med.
- 528 2015;12(10):e1001885. Epub 2015/10/07. doi: 10.1371/journal.pmed.1001885. PubMed PMID:
- 529 26440803; PubMed Central PMCID: PMCPMC4595218.
- 530 32. Osman M, van Schalkwyk C, Naidoo P, Seddon JA, Dunbar R, Dlamini SS, et al. Mortality during
- 531 tuberculosis treatment in South Africa using an 8-year analysis of the national tuberculosis treatment
- 532 register. Sci Rep. 2021;11(1):15894. Epub 2021/08/07. doi: 10.1038/s41598-021-95331-w. PubMed
- 533 PMID: 34354135; PubMed Central PMCID: PMCPMC8342475.
- 534 33. Jonnalagada S, Harries AD, Zachariah R, Satyanarayana S, Tetali S, Keshav Chander G, et al. The
- 535 timing of death in patients with tuberculosis who die during anti-tuberculosis treatment in Andhra
- 536 Pradesh, South India. BMC Public Health. 2011;11:921. Epub 2011/12/15. doi: 10.1186/1471-2458-11-
- 921. PubMed PMID: 22166132; PubMed Central PMCID: PMCPMC3254139.
- 538 34. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence
- 539 populations in sub-Saharan Africa. AIDS. 2001;15(2):143-52. Epub 2001/02/24. doi: 10.1097/00002030-
- 540 200101260-00002. PubMed PMID: 11216921.
- 541 35. Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM. High early death rate in
- tuberculosis patients in Malawi. Int J Tuberc Lung Dis. 2001;5(11):1000-5. Epub 2001/11/22. PubMed
- 543 PMID: 11716335.
- 544 36. Zachariah R, Fitzgerald M, Massaquoi M, Acabu A, Chilomo D, Salaniponi FM, et al. Does
- antiretroviral treatment reduce case fatality among HIV-positive patients with tuberculosis in Malawi?
- 546 Int J Tuberc Lung Dis. 2007;11(8):848-53. Epub 2007/08/21. PubMed PMID: 17705949.
- 547 37. Onyango DO, Yuen CM, Cain KP, Ngari F, Masini EO, Borgdorff MW. Reduction of HIV-associated
- excess mortality by antiretroviral treatment among tuberculosis patients in Kenya. PLoS One.
- 549 2017;12(11):e0188235. Epub 2017/11/18. doi: 10.1371/journal.pone.0188235. PubMed PMID:
- 29145454; PubMed Central PMCID: PMCPMC5690617.
- 38. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later start
- of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471-81.
- 553 Epub 2011/10/21. doi: 10.1056/NEJMoa1013911. PubMed PMID: 22010913; PubMed Central PMCID:
- 554 PMCPMC4879711.
- 555 39. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-
- exposure pro-phylaxis for HIV. Geneva, Switzerland2015.
- 557 40. Heunis JC, Kigozi NG, Chikobvu P, Botha S, van Rensburg HD. Risk factors for mortality in TB
- patients: a 10-year electronic record review in a South African province. BMC Public Health.
- 559 2017;17(1):38. Epub 2017/01/08. doi: 10.1186/s12889-016-3972-2. PubMed PMID: 28061839; PubMed
- 560 Central PMCID: PMCPMC5217308.

- 561 41. Limenh LW, Kasahun AE, Sendekie AK, Seid AM, Mitku ML, Fenta ET, et al. Tuberculosis
- treatment outcomes and associated factors among tuberculosis patients treated at healthcare facilities
- of Motta Town, Northwest Ethiopia: a five-year retrospective study. Sci Rep. 2024;14(1):7695. Epub
- 564 2024/04/03. doi: 10.1038/s41598-024-58080-0. PubMed PMID: 38565912; PubMed Central PMCID:
- 565 PMCPMC10987627.
- 566 42. Bukundi EM, Mhimbira F, Kishimba R, Kondo Z, Moshiro C. Mortality and associated factors
- among adult patients on tuberculosis treatment in Tanzania: A retrospective cohort study. J Clin Tuberc
- Other Mycobact Dis. 2021;24:100263. Epub 2021/08/07. doi: 10.1016/j.jctube.2021.100263. PubMed
- 569 PMID: 34355068; PubMed Central PMCID: PMCPMC8322306.
- 570 43. World Health Organization. Definitions and Reporting Framework for Tuberculosis—2013
- 571 Revision. Geneva2013.
- 572 44. World Health Organization. Global tuberculosis report 2022. Geneva2022.
- 573 45. Ter Beek L, Bolhuis MS, Jager-Wittenaar H, Brijan RXD, Sturkenboom MGG, Kerstjens HAM, et al.
- Malnutrition assessment methods in adult patients with tuberculosis: a systematic review. BMJ Open.
- 575 2021;11(12):e049777. Epub 2022/03/29. doi: 10.1136/bmjopen-2021-049777. PubMed PMID:
- 576 35344503; PubMed Central PMCID: PMCPMC8719177.
- 577 46. Bourke CD, Berkley JA, Prendergast AJ. Immune Dysfunction as a Cause and Consequence of
- 578 Malnutrition. Trends Immunol. 2016;37(6):386-98. Epub 2016/05/31. doi: 10.1016/j.it.2016.04.003.
- PubMed PMID: 27237815; PubMed Central PMCID: PMCPMC4889773.
- 580 47. Puplampu P, Kyeremateng I, Asafu-Adjaye O, Asare AA, Agyabeng K, Sarkodee R, et al.
- 581 Evaluation of treatment outcomes among adult patients diagnosed with tuberculosis in Ghana: A 10
- 582 year retrospective review. IJID Reg. 2024;10:9-14. Epub 2023/12/04. doi: 10.1016/j.ijregi.2023.11.004.
- PubMed PMID: 38045863; PubMed Central PMCID: PMCPMC10687693.
- 584 48. Lin Y, Enarson DA, Du J, Dlodlo RA, Chiang CY, Rusen ID. Risk factors for unfavourable treatment
- outcome among new smear-positive pulmonary tuberculosis cases in China. Public Health Action.
- 586 2017;7(4):299-303. Epub 2018/03/28. doi: 10.5588/pha.17.0056. PubMed PMID: 29584792; PubMed
- 587 Central PMCID: PMCPMC5753784.
- 588 49. Walker EF, Flook M, Rodger AJ, Fielding KL, Stagg HR. Quantifying non-adherence to anti-
- tuberculosis treatment due to early discontinuation: a systematic literature review of timings to loss to
- 590 follow-up. BMJ Open Respir Res. 2024;11(1). Epub 2024/02/16. doi: 10.1136/bmjresp-2023-001894.
- PubMed PMID: 38359965; PubMed Central PMCID: PMCPMC10875541.
- 592 50. Bantie B, Seid A, Kerebeh G, Alebel A, Dessie G. Loss to follow-up in "test and treat era" and its
- 593 predictors among HIV-positive adults receiving ART in Northwest Ethiopia: Institution-based cohort
- 594 study. Front Public Health. 2022;10:876430. Epub 2022/10/18. doi: 10.3389/fpubh.2022.876430.
- 595 PubMed PMID: 36249247; PubMed Central PMCID: PMCPMC9557930.
- 596 51. Kiwanuka J, Mukulu Waila J, Muhindo Kahungu M, Kitonsa J, Kiwanuka N. Determinants of loss
- 597 to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A
- retrospective cohort study in Masaka, Uganda. PLoS One. 2020;15(4):e0217606. Epub 2020/04/08. doi:
- 599 10.1371/journal.pone.0217606. PubMed PMID: 32255796; PubMed Central PMCID: PMCPMC7138304.
- 600 52. Monique O, Ilse DP. Factors Contributing to Pulmonary Tb Treatment Lost to Follow-up in
- 601 Developing Countries: An Overview. Afr J Infect Dis. 2023;17(1):60-73. Epub 2023/02/10. doi:
- 602 10.21010/Ajidv17i1.6. PubMed PMID: 36756489; PubMed Central PMCID: PMCPMC9885020.
- 603 53. Bhargava A, Bhargava M. Tuberculosis deaths are predictable and preventable: Comprehensive
- assessment and clinical care is the key. J Clin Tuberc Other Mycobact Dis. 2020;19:100155. Epub
- 605 2020/03/27. doi: 10.1016/j.jctube.2020.100155. PubMed PMID: 32211519; PubMed Central PMCID:
- 606 PMCPMC7082610.
- 607 54. Janse Van Rensburg A, Dube A, Curran R, Ambaw F, Murdoch J, Bachmann M, et al.
- 608 Comorbidities between tuberculosis and common mental disorders: a scoping review of epidemiological

- 609 patterns and person-centred care interventions from low-to-middle income and BRICS countries. Infect
- 610 Dis Poverty. 2020;9(1):4. Epub 2020/01/17. doi: 10.1186/s40249-019-0619-4. PubMed PMID: 31941551;
- PubMed Central PMCID: PMCPMC6964032.
- 612 55. Myburgh H, Baloyi D, Loveday M, Meehan SA, Osman M, Wademan D, et al. A scoping review of
- patient-centred tuberculosis care interventions: Gaps and opportunities. PLOS Glob Public Health.
- 614 2023;3(2):e0001357. Epub 2023/03/25. doi: 10.1371/journal.pgph.0001357. PubMed PMID: 36963071;
- PubMed Central PMCID: PMCPMC10021744.

- 616 56. Maynard C, Tariq S, Sotgiu G, Migliori GB, van den Boom M, Field N. Psychosocial support
- 617 interventions to improve treatment outcomes for people living with tuberculosis: a mixed methods
- 618 systematic review and meta-analysis. EClinicalMedicine. 2023;61:102057. Epub 2023/07/17. doi:
- 619 10.1016/j.eclinm.2023.102057. PubMed PMID: 37457116; PubMed Central PMCID: PMCPMC10338299.

Fig 1. Annual trend in: a) Successful TB treatment, b) Deaths and LTFU, c) Incidence rate of LTFU by sub-counties and d) Incidence rate of mortality by sub-counties.
 Panel a represents annual percentage of successful TB treatment while b, c and d are LTFU or deaths rates per 1000 person-years.
 Fig 2. Cumulative Hazard of LTFU by: a) Patient Type, b) HIV status and Cumulative Hazard for deaths by: c) age in years and d) HIV status.

Tables and Figures

630

631

Table 1. Patient characteristics at the time of starting TB treatment.

Characteristics	N=38020
Sex	
Male	27608 (73)
Female	10412 (27)
Age in years	
15 to 24	9233 (24)
25 to 34	11830 (31)
35 to 44	8619 (23)
45 to 54	4383 (12)
55 to 64	2175 (5.7)
≥65	1780 (4.7)
Year of starting TB treatment	, ,
2012	2860 (7.5)
2013	3137 (8.3)
2014	3337 (8.8)
2015	3025 (8.0)
2016	2939 (7.7)
2017	3826 (10)
2018	4250 (11)
2019	3879 (10)
2020	3382 (8.9)
2021	3577 (9.4)
2022	3808 (10)
Sub-County	
Buuri	8295 (22)
Igembe North	4245 (11)
Igembe South	5596 (15)
Imenti North	6030 (16)
Imenti South	6496 (17)
Meru Central	2761 (7.3)
Tigania East	1606 (4.2)
Tigania West	2991 (7.9)
Treatment facility type	
Public health facility	29972 (79)
Private health facility	7262 (19)
Prisons	786 (2.1)
BMI group	
Undernourished (BMI<18.5)	21331 (56)
Normal (BMI 18.5 to 24.9)	12573 (33)
Overweight (BMI ≥25)	1529 (4.0)
Unknown/missing	2587 (6.8)
TB diagnosis	
Bacteriologically confirmed	26599 (70)

Clinical signs and X-ray	11421 (30)
Patient category*	11421 (30)
New case	22070 (80)
	33979 (89)
Re-treatment after relapse	2333 (6.1)
Re-treatment after LTFU	851 (2.2)
Transfer in	652 (1.7)
Treatment after failure	205 (0.5)
Type of TB	
Pulmonary TB	33399 (88)
Extra-Pulmonary TB	4621 (12)
HIV status	
Negative	30186 (79)
Infected	6773 (18)
Unknown/missing	1061 (2.8)
HIV treatment (ARVs) n=6773	
Started taking ARVs	6350 (94)
Not yet	423 (6.3)
On cotrimoxazole prophylaxis (n=6773)	
Yes	6698 (99)
No	75 (1.0)
Other comorbidity*	280 (0.7)
On recreation drugs\$	1594 (4.2)
Direct observed treatment (dot)	
Family-based	35415 (93)
Community health Volunteer	262 (0.7)
Healthcare worker	2343 (6.2)
Treatment regimen	. ,
2RHZE/4RH	36011 (95)
2SRHZE/1RHZE/5RHE	1350 (3.6)
2RHZ/4RH	304 (0.8)
RHZE/10RH	195 (0.5)
Others	160 (0.4)
Nutritional support	- 2 (2)
No food support	7268 (19)
Therapeutic/Supplementary food	14924 (39)
Counselling only	15828 (42)
Counselling only	13020 (72)

^{*;76} kidney disease, 52 hypertension, 18 neurodevelopmental disorders, 11 chronic obstructive pulmonary disease, 3 cancer, 3 asthma and 3 COVID-19, \$;use of alcohol and smoking

Table 2. Lost-to-follow-up (LTFU) and mortality rates per 1000 person-years.

		LTFU (N=2385)		Deaths (N=1942)		
	N (%)	Rate/1000	Log-	N (%)	Rate/1000	Log-
Characteristics		person-years	rank		person-years	rank
		(95% CI)	P-		(95% CI)	P-
		()	value			value
Sex						
Male	1914 (6.9)	160 (153–167)	<0.001	1334 (4.8)	111 (106–118)	0.0002
Female	471 (4.5)	103 (94–113)	<0.001	608 (5.8)	133 (123-144)	0.0002
Age in years						
15 to 24	618 (6.7)	151 (140–164)		206 (2.2)	50 (44-58)	
25 to 34	900 (7.6)	175 (164–186)]	466 (3.9)	90 (83-99)]
35 to 44	496 (5.8)	132 (121–144)	<0.001	462 (5.4)	123 (112-135)	<0.001
45 to 54	219 (5.0)	116 (101–132)	<0.001	315 (7.2)	166 (149-186)	<0.001
55 to 64	85 (3.9)	93 (75–114)	1	219 (10)	238 (209-272)]
≥65	67 (3.8)	92 (72–117)	1	274 (15)	377 (335-424)]
Year of starting TB treatment						
2012	224 (7.8)	180 (158–206)		144 (5.0)	116 (99-137)	
2013	256 (8.2)	186 (165–211)	1	151 (4.8)	110 (94-129)	1
2014	196 (5.9)	133 (116–153)		180 (5.4)	122 (106-141)	1
2015	158 (5.2)	118 (101–138)		143 (4.7)	107 (91-126)	1
2016	189 (6.4)	148 (128–171)		149 (5.1)	117 (99-137)	
2017	315 (8.2)	193 (173–215)	< 0.001	172 (4.5)	105 (91-122)	0.03
2018	258 (6.1)	141 (125–159)		210 (4.9)	115 (100-131)	
2019	218 (5.6)	130 (114–148)		181 (4.7)	108 (93-125)	1
2020	170 (5.0)	115 (99–134)		164 (4.9)	111 (96-130)	1
2021	224 (6.3)	144 (126–164)		207 (5.8)	133 (116-153)	1
2022	177 (4.7)	107 (92–124)		241 (6.3)	146 (128-165)	1
Treatment facility type						
Public health facility	2000 (6.7)	153 (147–160)		1475 (4.9)	113 (107-119)	
Private health facility	348 (4.8)	110 (99–122)	< 0.001	441 (6.1)	140 (127-153)	0.0001
Prisons	37 (4.7)	114 (83–158)		26 (3.3)	80 (55-118)	
BMI group						
Undernourished	1395 (6.5)	151 (143–159)		1152 (5.4)	124 (117-132)	
Normal	688 (5.5)	124 (115–134)		501 (3.9)	91 (83-99)	
Overweight	68 (4.5)	101 (80–128)	< 0.001	69 (4.5)	103 (81-130)	< 0.001
Unknown/missing	234 (9.1)	218 (191–247)		220 (8.5)	205 (179-234)	
TB diagnosis						
Bacteriological	1826 (6.9)	156 (149–163)	.0.001	882 (3.3)	75 (70-80)	.0.001
Clinical signs	559 (4.9)	116 (107–126)	< 0.001	1060 (9.3)	220 (207-234)	< 0.001
Patient category						
New case	2025 (5.9)	137 (131–143)		1675 (4.9)	113 (108-119)	
Re-treatment after relapse	122 (5.2)	121 (101–145)		179 (7.7)	178 (153-206)	
Re-treatment after LTFU	172 (20)	519 (447–602)	<0.001	64 (7.5)	193 (151-247)	< 0.001
Transfer in	42 (6.4)	146 (108–197)	-0.001	23 (3.5)	80 (53-120)	10.001
Treatment after failure	24 (12)	268 (180–400)	1	1 (0.5)	11 (1.58-79)	1
Type of TB	27 (12)	200 (100-400)		1 (0.5)	11 (1.50-77)	
Pulmonary TB	2208 (6.6)	152 (145–158)		1546 (4.6)	106 (101-112)	
Extra-Pulmonary TB	177 (3.8)	90 (78–104)	< 0.001	396 (8.6)	202 (183-222)	< 0.001
HIV status	1//(3.0)	90 (70 - 10 4)		390 (8.0)	202 (103-222)	
Negative Negative	1821 (6.0)	136 (131–143)		1118 (3.7)	84 (79-89)	
		 	< 0.001	730 (11)	260 (241-280)	< 0.001
Infected	449 (6.6)	160 (146–175)	1	/30 (11)	ZUU (Z41-Z8U)	1

Unknown/missing	115 (11)	271 (226–326)		J94 (8.9)	222 (181-271)	
Other comorbidity (Not HIV)						
No	2376 (6.3)	145 (139-151)	0.07	1890 (5.0)	115 (110-120)	<0.001
Yes	9 (3.2)	81 (42-156)	0.07	52 (19)	470 (358-617)	<0.001
On recreation drugs						
No	2282 (6.3)	144 (138-150)	0.73	1857 (5.1)	117 (112-123)	0.63
Yes	103 (6.5)	152 (125-184)	0.73	85 (5.3)	125 (101-155)	0.03
Direct observed treatment (dot)						
Family-based	2210 (6.2)	144 (138–150)		1795 (5.1)	117 (111-122)	
Community health	17(6.5)	153 (95–246)	0.69	14 (5.3)	126 (74-212)	0.52
Volunteer			0.09			0.32
Healthcare worker	158 (6.7)	151 (130–177)	1	133 (5.7)	128 (108-151)	
Treatment regimen						
2RHZE/4RH	2196 (6.1)	140 (134–146)		1800 (5.0)	115 (110-120)	
2SRHZE/1RHZE/5RHE	162 (12)	283 (242–330)		103 (7.6)	180 (148-218)	
2RHZ/4RH	12 (4.0)	90 (51–158)	< 0.001	13 (4.3)	97 (57-168)	< 0.001
RHZE/10RH	14 (7.2)	171 (101–289)		20 (10)	245 (158-379)	
Others	1 (0.6)	13.6 (1.91–96)		6 (3.8)	81 (37-181)	

All P-values are from log-rank test, the rates are per 1000 person-years.

Table 3. Multivariable analysis of patient characteristics associated with LTFU and mortality within six months of starting TB treatment.

639

Characteristics	LTFU		Mortality			
	aSHR (95%CI)	P-value	aSHR (95%CI)	p-value		
Sex						
Male	Reference		¶			
Female	0.64 (0.60-0.69)	<0.001	¶			
Age in years	,					
15 to 24	Reference		Reference			
25 to 34	1.09 (0.96-1.23)	0.18	1.57 (1.42-1.74)	<0.001		
35 to 44	0.83 (0.73-0.95)	0.008	1.89 (1.55-2.39)	<0.001		
45 to 54	0.75 (0.62-0.90)	0.002	2.40 (2.04–2.81)	<0.001		
55 to 64	0.60 (0.44-0.82)	0.001	3.48 (2.90-4.17)	<0.001		
≥65	0.63 (0.51-0.78)	<0.001	5.86 (4.82-7.13)	<0.001		
Year of starting TB treatment	,		, ,			
2012	Reference		Reference			
2013	1.06 (0.94-1.18)	0.34	0.98 (0.77-1.26)	0.91		
2014	0.71 (0.51–1.00)	0.05	1.13 (0.89–1.44)	0.31		
2015	0.67 (0.56–0.80)	<0.001	1.24 (0.97–1.59)	0.08		
2016	0.85 (0.60-1.19)	0.34	1.42 (1.12-1.80)	0.004		
2017	1.10 (0.87-1.40)	0.41	1.09 (0.93-1.29)	0.29		
2018	0.83 (0.74–0.93)	0.001	1.15 (0.86–1.54)	0.34		
2019	0.76 (0.61–0.94)	0.01	1.14 (0.90–1.46)	0.29		
2020	0.67 (0.55-0.81)	<0.001	1.20 (0.95-1.51)	0.14		
2021	0.81 (0.59-1.13)	0.21	1.34 (1.05-1.70)	0.02		
2022	0.61 (0.48-0.77)	<0.001	1.40 (1.17-1.67)	<0.001		
Treatment facility type						
Public health facility	Reference		Reference			
Private health facility	0.78 (0.60-1.00)	0.05	0.85 (0.69-1.06)	0.15		
Prisons	0.62 (0.47-0.82)	0.001	0.70 (0.55-0.90)	0.006		
BMI group						
Undernourished (BMI<18.5)	¶		1.50 (1.40–1.61)	<0.001		
Normal (BMI 18.5 to 24.9)	¶		Reference			
Overweight (BMI ≥25)	¶		0.86 (0.76–0.98)			
Unknown/missing	¶		2.06 (1.61–2.63)	<0.001		
TB diagnosis			,			
Bacteriologically confirmed	Reference		Reference			
Clinical signs and X- ray	0.85 (0.73-0.99)	0.03	2.22 (1.97–2.49)	<0.001		
Patient category						
New case	Reference		Reference			

0.77 (0.67–0.99)	0.001	1.43 (1.12–1.82)	0.004
3.28 (2.59-4.17)	<0.001	1.59 (0.93-2.73)	0.09
1.06 (0.69-1.63)	0.79	0.75 (0.40-1.39)	0.36
2.11 (1.66–2.68)	<0.001	1.39 (0.77-2.49)	0.27
1.65 (1.27-2.14)	<0.001	0.15 (0.02-1.19)	0.07
Reference		¶	
0.72 (0.60-0.86)	<0.001	¶	
Reference		Reference	
1.24 (1.07-1.44)	0.003	2.41 (2.04–2.85)	<0.001
2.30 (1.90-3.03)	<0.001	5.03 (3.56-7.10)	<0.001
1.83 (1.26-2.65)	0.001	0.001 2.27 (1.79–2.88)	
¶		2.67 (1.78-4.01)	<0.001
Reference		Reference	
1.34 (1.13-1.58)	0.001	1.13 (0.86-1.50)	0.37
0.62 (0.33-1.18)	0.15	0.91 (0.47-1.79)	0.79
1.54 (0.87-2.73)	0.14	1.51 (1.06-2.15)	0.02
0.13 (0.59-0.30)	<0.001	0.50 (0.15-1.75)	0.28
	3.28 (2.59–4.17) 1.06 (0.69–1.63) 2.11 (1.66–2.68) 1.65 (1.27–2.14) Reference 0.72 (0.60–0.86) Reference 1.24 (1.07–1.44) 2.30 (1.90–3.03) 1.83 (1.26–2.65) ¶ Reference 1.34 (1.13–1.58) 0.62 (0.33–1.18) 1.54 (0.87–2.73)	3.28 (2.59–4.17) <0.001 1.06 (0.69–1.63)	3.28 (2.59–4.17)

^{¶;} independent variables not selected for inclusion in multivariable model, aSHR; adjusted Sub-distribution Hazard Ratio, aSHR are from multilevel competing risk analysis models.




Fig 1a




Fig 1b




Fig 1c




Fig 1d




Fig 2a




Fig 2b




Fig 2c




Fig 2d